Pyridine derivatives as agonists of the CB2 receptor

US9321727B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Caterina Bissantz · Rixheim, FR
• Uwe Grether · Weil am Rhein, DE
• Paul Hebeisen · Basel, CH
• Atsushi Kimbara · Tokyo, JP
• Qingping Liu · Beijing, CN
• Matthias Nettekoven · Weil am Rhein, DE
• Marco Prunotto · Basel, CH
• Stephan Roever · Inzlingen, DE
• Mark Rogers-Evans · Bottmingen, CH
• Tanja Schulz-Gasch · Ziefen, CH
• Christoph Ullmer · Fischingen, DE
• Zhiwei Wang · Beijing, CN
• Wulun Yang · Beijing, CN

Key dates

• Filing date: Jun 1, 2012
• Grant date: Apr 26, 2016
• Expiry date: Aug 8, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/107
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a compound of formula (I)Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases.A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.